Prescribing information


Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

If you would like to hear about upcoming events, you can sign up to receive our email communications.

Recordings from our latest events



Bringing innovation into clinical practice: a national approach to lipid management

Watch Professor Julia Newton, Medical Director North East & North Cumbria AHSN and Executive Lead for the NHS AAC/AHSN National Lipid Management and Familial Hypercholesterolaemia Programme, discuss how the AHSN, the AAC and Novartis are working together (with the support of NHS Digital) to help identify, treat, and monitor eligible patients with ASCVD through the optimisation of the national lipid management pathway, which includes inclisiran.


Introducing inclisiran to address the current challenges in ASCVD and lipid management

Watch Dr Yassir Javaid, GPwSI in Cardiology, introduce inclisiran as a LDL-C lowering therapy to address the current challenges in lipid management and how it can support the NHS long term plan.


Recordings by topic



Introduction to inclisiran

Watch Dr Jaimini Cegla provide an overview of key inclisiran product information, including safety and efficacy data from the Phase III ORION-10 and ORION-11 clinical trials.2


Cholesterol and cardiovascular disease management

Watch Dr Matt Kearney discuss why cholesterol and cardiovascular disease management is a key focus for NHS England right now.



AAC, Accelerated Access Collaborative; AHSN, Academic Health Science Network; ASCVD, atherosclerotic cardiovascular disease; GPwSI, general practitioner with special interest; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service.


  1. Leqvio® Summary of Product Characteristics.
  2. Ray KK et al. N Engl J Med 2020;382(16):1507–1519.
Rate this content: 
No votes yet
UK | December 2022 | 255512

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]